BR112022025880A2 - Administração de antagonista de cebp-beta e métodos de uso - Google Patents

Administração de antagonista de cebp-beta e métodos de uso

Info

Publication number
BR112022025880A2
BR112022025880A2 BR112022025880A BR112022025880A BR112022025880A2 BR 112022025880 A2 BR112022025880 A2 BR 112022025880A2 BR 112022025880 A BR112022025880 A BR 112022025880A BR 112022025880 A BR112022025880 A BR 112022025880A BR 112022025880 A2 BR112022025880 A2 BR 112022025880A2
Authority
BR
Brazil
Prior art keywords
methods
cebp
antagonist administration
beta
beta antagonist
Prior art date
Application number
BR112022025880A
Other languages
English (en)
Inventor
Jay Kappel Barry
Merutka Gene
Andrew Rotolo Jimmy
e michel Robert
Susannah Bexon Alice
Original Assignee
Sapience Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapience Therapeutics Inc filed Critical Sapience Therapeutics Inc
Publication of BR112022025880A2 publication Critical patent/BR112022025880A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ADMINISTRAÇÃO DE ANTAGONISTA DE CEBP-BETA E MÉTODOS DE USO. São fornecidos métodos de administração de um antagonista peptídico da proteína beta de ligação a CCAAT/potenciador (C/EBPß) e métodos de tratamento de tumores sólidos por administração de um antagonista peptídico de C/EBPß.
BR112022025880A 2020-06-21 2021-06-21 Administração de antagonista de cebp-beta e métodos de uso BR112022025880A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063041990P 2020-06-21 2020-06-21
US202063041991P 2020-06-21 2020-06-21
US202063041989P 2020-06-21 2020-06-21
US202063041986P 2020-06-21 2020-06-21
US202063041988P 2020-06-21 2020-06-21
US202163172560P 2021-04-08 2021-04-08
PCT/US2021/038264 WO2021262604A2 (en) 2020-06-21 2021-06-21 Administration of cebp-beta antagonist and methods of use

Publications (1)

Publication Number Publication Date
BR112022025880A2 true BR112022025880A2 (pt) 2023-01-10

Family

ID=79281738

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025880A BR112022025880A2 (pt) 2020-06-21 2021-06-21 Administração de antagonista de cebp-beta e métodos de uso

Country Status (11)

Country Link
US (1) US20230218717A1 (pt)
EP (1) EP4168033A2 (pt)
JP (1) JP2023531683A (pt)
KR (1) KR20230027054A (pt)
CN (1) CN115768458A (pt)
AU (1) AU2021297172A1 (pt)
BR (1) BR112022025880A2 (pt)
CA (1) CA3180559A1 (pt)
IL (1) IL299104A (pt)
MX (1) MX2022016478A (pt)
WO (1) WO2021262604A2 (pt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6752222B2 (ja) * 2015-04-16 2020-09-09 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 羞明を処置、予防、または阻害するための抗ｐａｃａｐ抗体及びそれらの抗原結合性断片の使用
CA3086768C (en) * 2018-01-03 2023-09-26 Barry Jay Kappel Atf5 peptide variants and uses thereof
WO2020033555A2 (en) * 2018-08-08 2020-02-13 The Trustees Of Columbia University In The City Of New York Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells

Also Published As

Publication number Publication date
CN115768458A (zh) 2023-03-07
KR20230027054A (ko) 2023-02-27
WO2021262604A3 (en) 2022-02-17
JP2023531683A (ja) 2023-07-25
CA3180559A1 (en) 2021-12-30
MX2022016478A (es) 2023-02-01
US20230218717A1 (en) 2023-07-13
EP4168033A2 (en) 2023-04-26
WO2021262604A2 (en) 2021-12-30
AU2021297172A1 (en) 2023-01-19
IL299104A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
BR112022008534A2 (pt) Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
SI3079715T1 (en) A mixture of peptides
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
PE20200303A1 (es) Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
BR112021017399A2 (pt) Proteína de fusão bifuncional e uso farmacêutico da mesma
CY1124916T1 (el) Υγρο σκευασμα νευροτοξινης σταθεροποιημενο με τρυπτοφανη ή τυροσινη
BR112015022856A8 (pt) inibidores de protease de cetona de epóxi de tripeptídeo e dipeptídeo
MX2021014601A (es) Proteinas recombinantes de union a fap y su uso.
BR112022010153A2 (pt) Peptídeos, ácido nucleico, polipeptídeo, composição, complexo bioluminescente, métodos, dipeptídeo, sistema e kit
CL2020003292A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
RU2010111139A (ru) Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства
BR112023000270A2 (pt) Composto, composição farmacêutica, e, peptídeo
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
EA202192726A1 (ru) Magea1-специфические т-клеточные рецепторы и их использование
FI3463436T3 (fi) Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää
WO2022272033A8 (en) Extended-release immune cell engaging proteins and methods of treatment
BR112022025880A2 (pt) Administração de antagonista de cebp-beta e métodos de uso
BR112021000899A2 (pt) Peptídeos de ligação a il-17a e usos médicos dos mesmos
EA202191651A1 (ru) Бициклические пептидные лиганды, специфичные к mt1-mmp
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
BR112023003265A2 (pt) Inibidores de secreção de proteínas
BR112023000229A2 (pt) Composto, composição farmacêutica, e, peptídeo
BR112022013978A2 (pt) Peptídeo isolado, e, composição farmacêutica

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: SAPIENCE THERAPEUTICS, INC. (US)